LJI Wealth Management LLC Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

LJI Wealth Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 2.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 5,058 shares of the company’s stock after selling 112 shares during the period. LJI Wealth Management LLC’s holdings in Johnson & Johnson were worth $739,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Innealta Capital LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Christopher J. Hasenberg Inc bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth $43,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth $44,000. Finally, Fairfield Financial Advisors LTD bought a new stake in Johnson & Johnson in the 2nd quarter valued at $46,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. The Goldman Sachs Group decreased their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. TD Securities reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $166.17 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a market capitalization of $399.92 billion, a price-to-earnings ratio of 10.36, a PEG ratio of 2.71 and a beta of 0.53. The firm’s 50-day moving average is $160.71 and its 200 day moving average is $154.09.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the business posted $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.